# Cell Surface Marker Expression in Autoimmune Diseases

> **NCT03757065** · — · COMPLETED · sponsor: **Alpine Immune Sciences, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Sjogren's Syndrome
- Multiple Sclerosis
- Systemic Sclerosis
- Crohn's Disease
- Ulcerative Colitis
- Inflammatory Myositis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03757065
- **Lead sponsor:** Alpine Immune Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-10-25
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757065, "Cell Surface Marker Expression in Autoimmune Diseases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03757065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*